CLAIM AMENDMENTS:

This listing of claims will replace all prior versions and listing of claims in the application.

Listing of the Claims:

Claims 1-4 (**cancelled**).

Claim 5 (**currently amended):** A compound of the formula IIb:



(IIb)

wherein:

M is -CH- or -N-;

nc is 0, 1 or 2;

R^{2c} is linked to a carbon atom of the 5-membered ring and is selected from hydrogen and methyl;

R^{2d} is linked to a carbon atom of the 6-membered ring and is selected from hydrogen and fluoro;

R^{2a} and R^{2b} are each independently selected from hydrogen, hydroxy, halogeno, cyano, nitro, trifluoromethyl, C_{1-3}alkyl, C_{1-3}alkoxy, C_{1-3}alkylsulphanyl, $-NR^{3a}R^{4a}$ (wherein R^{3a} and R^{4a}, which may be the same or different, each represents hydrogen or C_{1-}

$_3$alkyl), and Q^1X^1

wherein Q^1 is selected from one of the following groups:

1) C_{1-4}alkyl-Q^{13}-C(O)-C_{1-4}alkyl-Q^{14} wherein Q^{13} and Q^{14} are each independently selected from pyrrolidinyl, piperidinyl, piperazinyl,


and

,

wherein Q^{14} is linked to C_{1-4}alkanoyl ~~C_{1-6}alkanoyl~~ through a nitrogen atom;

2) Q^2 (wherein Q^2 is a 5-6-membered heterocyclic group selected from pyrrolidinyl, piperidinyl, piperazinyl,


and

,

which heterocyclic group bears either one substituent selected from methylenedioxy or ethylenedioxy to form a bicyclic ring, or bears at least one substituent selected from C_{2-4}alkanoylC_{1-3}alkyl and optionally bears a further 1 or 2 substituents selected from C_{2-5}alkenyl, C_{2-5}alkynyl, C_{1-6}fluoroalkyl, C_{1-6}alkanoyl, C_{2-4}alkanoylC_{1-3}alkyl, aminoC_{1-6}alkanoyl, C_{1-4}alkylaminoC_{1-6}alkanoyl, di(C_{1-4}alkyl)aminoC_{1-6}alkanoyl, C_{1-6}fluoroalkanoyl, carbamoyl, C_{1-4}alkylcarbamoyl, di(C_{1-4}alkyl)carbamoyl, carbamoylC_{1-6}alkyl, C_{1-4}alkylcarbamoylC_{1-6}alkyl, di(C_{1-4}alkyl)carbamoylC_{1-6}alkyl, C_{1-6}alkylsulphonyl, C_{1-6}fluoroalkylsulphonyl, oxo, hydroxy, halogeno, cyano, C_{1-4}cyanoalkyl, C_{1-4}alkyl, C_{1-4}hydroxyalkyl, C_{1-4}alkoxy, C_{1-4}alkoxyC_{1-4}alkyl, C_{1-4}alkylsulphonylC_{1-4}alkyl, C_{1-4}alkoxycarbonyl, C_{1-4}aminoalkyl, C_{1-4}alkylamino, di(C_{1-4}alkyl)amino, C_{1-4}alkylaminoC_{1-4}alkyl, di(C_{1-4}alkyl)aminoC_{1-4}alkyl, C_{1-4}alkylaminoC_{1-4}alkoxy, di(C_{1-4}alkyl)aminoC_{1-4}alkoxy and a group -(-O-)$_f$(C_{1-4}alkyl)$_g$ringD (wherein f is 0 or 1, g is 0 or 1 and ring D is a 5-6-membered saturated or partially unsaturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and

N, which cyclic group may bear one or more substituents selected from C_{1-4}alkyl)); and

3) C_{1-5}alkylQ^2 (wherein Q^2 is as defined herein);

and X^1 is O;

and additionally wherein any C_{1-5}alkyl group in Q^1X^1- which is linked to X^1 may bear one or more substituents selected from hydroxy, halogeno and amino;

Z^a is -O- or -S-;

with the proviso that at least one of R^{2a} and R^{2b} is Q^1X^1 wherein Q^1 and X^1 are as defined herein;

or a pharmaceutically-acceptable salt thereof.

Claim 6 (**currently amended**): The ~~A~~ compound according to claim 5 wherein one of R^{2a} and R^{2b} is methoxy and the other is Q^1X^1 wherein X^1 and Q^1 are as defined in claim 5.

Claim 7 (**currently amended**): The ~~A~~ compound according to claim 5 wherein one of R^{2a} and R^{2b} is methoxy and the other is Q^1X^1 wherein X^1 is -O- and Q^1 is C_{1-4}alkyl-Q^{13}-C(O)-C_{1-4}alkyl-Q^{14} wherein Q^{13} and Q^{14} are each independently selected from pyrrolidinyl, piperidinyl, piperazinyl,



and



,

wherein Q^{14} is linked to C_{1-6}alkanoyl through a nitrogen atom.

Claim 8 (**currently amended**): The ~~A~~ compound according to claim 5 wherein one of R^{2a} and R^{2b} is methoxy and the other is Q^1X^1 wherein X^1 is -O- and Q^1 is selected from one of the following groups:

1) Q^2 (wherein Q^2 is a 5-6-membered heterocyclic group selected from pyrrolidinyl, piperidinyl, piperazinyl,

 and  ,

which heterocyclic group bears either one substituent selected from methylenedioxy or ethylenedioxy to form a bicyclic ring, or bears one substituent selected from C_{2-4}alkanoylC_{1-3}alkyl; and

2) C_{1-5}alkylQ^2 (wherein Q^2 is as defined herein).

Claim 9 (**currently amended**): The ~~A~~ compound according to claim 7 or claim 8 wherein R^{2a} is methoxy.

Claim 10 (**currently amended**): The ~~A~~ compound according to claim 5 selected from:

7-{[1-(acetylmethyl)piperidin-4-yl]methoxy}-6-methoxy-4-[(3-methyl-1*H*-indol-5-yl)oxy]quinazoline,

~~7-{[1-(acetylmethyl)piperidin-4-yl]methoxy}-6-methoxy-4-[(2-methyl-1*H*-indol-6-yl)oxy]quinazoline,~~

7-{[1-(acetylmethyl)piperidin-4-yl]methoxy}-6-methoxy-4-[(2-methyl-1*H*-indol-5-yl)oxy]quinazoline,

6-methoxy-4-[(3-methyl-1*H*-indol-5-yl)oxy]-7-{[1-(pyrrolidin-1-ylacetyl)piperidin-4-yl]methoxy}quinazoline,

~~6-methoxy-4-[(2-methyl-1*H*-indol-6-yl)oxy]-7-{[1-(pyrrolidin-1-ylacetyl)piperidin-4-yl]methoxy}quinazoline,~~

6-methoxy-4-[(2-methyl-1*H*-indol-5-yl)oxy]-7-{[1-(pyrrolidin-1-ylacetyl)piperidin-4-yl]methoxy}quinazoline,

6-methoxy-4-[(2-methyl-1*H*-indol-5-yl)oxy]-7-[2-(tetrahydro-5*H*-[1,3]dioxolo[4,5-*c*]pyrrol-5-yl)ethoxy]quinazoline,

6-methoxy-4-[(3-methyl-1*H*-indol-5-yl)oxy]-7-[2-(tetrahydro-5*H*-[1,3]dioxolo[4,5-*c*]pyrrol-5-yl)ethoxy]quinazoline,

4-[(2,3-dimethyl-1*H*-indol-5-yl)oxy]-6-methoxy-7-[2-(tetrahydro-5*H*-[1,3]dioxolo[4,5-*c*]pyrrol-5-yl)ethoxy]quinazoline,

4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-6-methoxy-7-[2-(tetrahydro-5*H*-[1,3]dioxolo[4,5-*c*]pyrrol-5-yl)ethoxy]quinazoline,

7-{2-[4-(acetylmethyl)piperazin-1-yl]ethoxy}-4-[(2,3-dimethyl-1*H*-indol-5-yl)oxy]-6-methoxyquinazoline,

7-{2-[4-(acetylmethyl)piperazin-1-yl]ethoxy}-6-methoxy-4-[(3-methyl-1*H*-indol-5-yl)oxy]quinazoline,

7-{2-[4-(acetylmethyl)piperazin-1-yl]ethoxy}-6-methoxy-4-[(2-methyl-1*H*-indol-5-yl)oxy]quinazoline,

7-{2-[4-(acetylmethyl)piperazin-1-yl]ethoxy}-4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-6-methoxyquinazoline,

6-methoxy-4-[(2-methyl-1*H*-indol-5-yl)oxy]-7-{2-[4-(pyrrolidin-1-ylacetyl)piperazin-1-yl]ethoxy}quinazoline,

~~7-{[1-(acetylmethyl)piperidin-4-yl]oxy}-6-methoxy-4-[(2-methyl-1*H*-indol-6-yl)oxy]quinazoline,~~

7-{[1-(acetylmethyl)piperidin-4-yl]oxy}-6-methoxy-4-[(2-methyl-1*H*-indol-5-yl)oxy]quinazoline, and

7-{[1-(acetylmethyl)piperidin-4-yl]oxy}-4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-6-methoxyquinazoline,

and pharmaceutically-acceptable salts thereof.

Claims 11 - 13 (**cancelled**).

Claim 14 (**previously presented**): A pharmaceutical composition which comprises a compound of the formula IIb as defined in claim 5 or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable excipient or carrier.

Claim 15 (**cancelled**)

.

Claim 16 (**currently amended; withdrawn**): A method for producing an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal~~,~~ ~~such as a human being,~~ in need of such treatment which comprises administering to said animal an effective amount of a compound of formula IIb as defined in claim 5 or a pharmaceutically acceptable salt thereof.